Formoterol Reverses Fatty Liver Damage, Sparking Clinical Trials
A decades-old asthma drug, formoterol, reversed fatty liver damage in mice modeling MASH and showed associations with fewer severe liver complications in people taking beta-2 agonists; MUSC researchers are moving to human trials to test whether the drug can treat MASH and diabetic kidney disease by boosting beta-2 signaling and mitochondrial biogenesis, though causal proof in humans is not yet established.